Home Page Overall Ranking ROE Ranking P/E Ranking Dividend Yield Capitalization Our eBook Our Book Contact










Isin IT0003828271
Ticker REC.MI
Company RECORDATI
Currency
Price
Aware Investor Index (AII) 0.0470
Recommendation SELL
P/E 77.77
ROE 13.87 %
Capitalization 10,199,164,760 $
Dividend Yield 1.31 %
P/S 8.96
AII Position 559
P/E Position 701
ROE Position 281
Capitalization Position 495
Dividend Yield Position 462
Sales 1,047,676,000 €
10-Year Average Earnings 120,708,500 €
Shares Outstanding 205,270,094
Equity 869,992,000 €
Dividend per Share 0.6 €
Industry Pharmaceutical
Country Italy
RECORDATI Investor Relations Web Site http://www.recordati.it/it/investors/







Sales:

YEAR MONTH AMOUNT
2015 12 1,047,676,000.00 €
2014 12 987,356,000.00 €
2013 12 941,630,000.00 €

Earnings:

YEAR MONTH AMOUNT
2015 12 198,803,000.00 €
2014 12 161,193,000.00 €
2013 12 133,693,000.00 €
2012 12 118,500,000.00 €
2011 12 116,400,000.00 €
2010 12 108,600,000.00 €
2009 12 110,600,000.00 €
2008 12 100,400,000.00 €
2007 12 84,865,000.00 €
2006 12 74,031,000.00 €

Equity:

YEAR MONTH AMOUNT
2015 12 869,992,000.00 €
2014 12 787,422,000.00 €
2013 12 701,820,000.00 €
2012 12 661,397,000.00 €

Shares Outstanding:

YEAR MONTH AMOUNT
2015 12 205,270,094
2014 12 204,417,486
2013 12 202,615,046
2012 12 200,619,366

 












Bloomberg News for RECORDATI:

Oct 18, 2017
More Than Half the EU Is Still Racing to Comply With MiFID Rules
getting unofficially supportive feedback.”The MiFID II package consists of two main parts. The Markets in Financial Instruments Regulation, or MiFIR, is binding in its entirety and applies directly...
Oct 18, 2017
MiFID Not an Advantage for U.S. Research, Says Bevan
James Bevan, chief investment officer at CCLA Investment Management, examines the impact of MiFID II rules on research from the U.S. and Europe. He speaks with Bloomberg's Francine Lacqua on...
Oct 17, 2017
Goldman Sachs Asks for $30,000 for Research Post-MiFID
a year for up to 10 of their staff to access basic research through its analyst portal once the MiFID II rules come into force in January, according to people with knowledge of the matter.The package...
Oct 18, 2017
Wall Street Poised to Get a Key SEC Reprieve Over MiFID
investment funds. The practice, which keeps trading costs down, could be put in jeopardy by MiFID II.How MiFID II Puts a Price on Investment Research: QuickTake Q&AThe SEC’s guidance hasn’t been finalized...
Oct 18, 2017
SEC Said Providing a MiFID Reprieve to Wall Street
Source: Bloomberg, 01:49 The U.S. Securities and Exchange Commission is said...
Oct 18, 2017
SEC Mulls Reprieve Over MiFID II
Source: Bloomberg, 03:01 The U.S. SEC is preparing to tell financial firms...
Oct 18, 2017
Everything You Need to Know This Morning From Daybreak (Podcast)
cover the biggest stories that happened overnight. Wall Street is getting a MiFID reprieve and Goldman Sachs sets its MiFID price tag. Initial coin offerings may fall under CFTC oversight. Philadelphia...
Oct 13, 2017
UBS Chairman Weber on MiFID, ECB Policy and Brexit
UBS Chairman Axel Weber discusses MiFID rules, ECB policy and his plan to keep as many research analysts as possible in London after...
Oct 18, 2017
How Do You Put a Price on Investment Research?
corporations. Under the terms of MiFID II, managers that pass on costs to clients must regularly assess the quality of research they purchase.8. Will trading fees go down?Maybe. MiFID II requires investment...
Oct 18, 2017
Five Things You Need to Know to Start Your Day
chaos. More than half the EU is still racing to comply with MiFID rules…...With Wall Street set to get a key SEC reprieve over MiFID…...As Goldman are said to ask for $30,000 for research after...


Google News for RECORDATI:

MarketWatch - 21 May 2017
AstraZeneca, Recordati agree Seloken rights deal
LONDON--AstraZeneca PLC (AZN.LN) has entered into an agreement with Recordati S.p.A (REC.MI) for the commercial rights to AstraZeneca's ...
The Pharma Letter - 13 Apr 2017
Recordati Rare Diseases Canada launched
Recordati Rare Diseases Canada, a company wholly-owned by the Italy-based Recordati Group (REC: MI), will be the exclusive provider of ...
The Pharma Letter (subscription) - 13 Feb 2012
Recordati sales up, despite Zanidip patent loss
Italian drugmaker Recordati (REC: MI) on Friday reported full-year 2011 results, with consolidated revenue reaching 762.0 million euros ...
fabiotroglia.com (Blog) - 21 Jul 2016
Azioni Recordati, la pharma italiana che continua a brillare
Per noi non ci sono limiti per ora, abbiamo acquistato le azioni di Recordati (REC.MI) nel febbraio 2014 a 12 euro, puntavamo come target i 20 ...


Back